The Serum Institute will manufacture Novavax'sCovid vaccine, with the government aiming to produce 20 crore doses by December.

Novavax, a biotechnology company based in the United States, has partnered with the Serum Institute of India (SII) to manufacture its Covid-19 vaccine, dubbed Covovax. According to the business, phase 3 clinical trials showed that their nanoparticle protein-based vaccination had an overall efficacy of 90.4 percent.

Serum Institute of India, situated in Pune, is the world's largest vaccine maker in terms of doses produced and marketed worldwide. SII, according to Novavax, is a critical partner in meeting production goals. Although the business has not announced current production volumes, it has set a goal of producing roughly 50 million Covovax doses per month.

Novavax, known in India as Covavax, is nearing the end of Phase 2/3 “observer-blinded, randomized, active-controlled” bridging trials with SII, which will enroll 1,600 people over 18 years in 15 locations. SII has also expressed an interest in undertaking pediatric trials.

The company, which is based in Maryland, said it plans to file for regulatory permission in the third quarter of 2021. It stated that by the end of the third quarter, it would be on track to produce 100 million doses per month and 150 million doses per month by the end of the year.

SII would be permitted to launch the vaccine in India if Novavax receives Emergency Use Authorization in the United States, according to the new vaccine approval regulations. In India, SII has partnered with Novavax to make COVID-19 vaccines. In India, the vaccine was supposed to be released in September 2021.

Clinical trials of the vaccine 'Covovax' have begun in India, according to SII CEO Adar Poonawalla, and the company intends to sell it by September this year. The Covishield vaccine, a local equivalent of Oxford-medicine, AstraZeneca's is already being manufactured at the SII.

He had complained that due to a scarcity of raw materials caused by the US export prohibition, the manufacturing of the Novavax vaccine was being delayed in India. The crisis was resolved, however, as the US relaxed its raw material export restrictions last month.